Author: Lazzaroni, Maria Grazia; Piantoni, Silvia; Masneri, Stefania; Garrafa, Emirena; Martini, Giuliana; Tincani, Angela; Andreoli, Laura; Franceschini, Franco
Title: Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system Cord-id: 1rl7vxaa Document date: 2020_8_24
ID: 1rl7vxaa
Snippet: COVID-19 is a new pandemic, caused by Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-Cov2) infection and characterized by a broad spectrum of clinical manifestations. Inflammation and the innate immune system have been recently recognized as pivotal players in the most severe forms, characterized by significantly elevated levels of pro-inflammatory cytokines. In this setting, several studies have also reported the presence of abnormalities in coagulation parameters and platelets count, po
Document: COVID-19 is a new pandemic, caused by Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-Cov2) infection and characterized by a broad spectrum of clinical manifestations. Inflammation and the innate immune system have been recently recognized as pivotal players in the most severe forms, characterized by significantly elevated levels of pro-inflammatory cytokines. In this setting, several studies have also reported the presence of abnormalities in coagulation parameters and platelets count, possibly identifying a subgroup of patients with poor prognosis. Some reports of full-blown thromboembolic events are emerging. Among the possible mechanisms underlying coagulation dysfunction, the so-called cytokine storm seems to play a pivotal role. Other candidate factors include virus-specific mechanisms, related to the virus interaction with renin angiotensin system (RAS) and the fibrinolytic pathway, but also comorbidities affecting these patients. Coagulation dysfunction is therefore a candidate risk factor for adverse outcomes in COVID-19 and should be carefully addressed in clinical practice.
Search related documents:
Co phrase search for related documents- ace activity and acute lung disease: 1
- ace activity and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8
- ace activity and admission time: 1
- ace activity and local systemic: 1
- ace inhibitor and acute effect: 1
- ace inhibitor and acute injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- ace inhibitor and acute lung injury: 1, 2, 3, 4
- ace inhibitor and admission time: 1
- ace inhibitor and local regulation: 1
- ace inhibitor and local systemic: 1
- acute effect and admission time: 1, 2, 3
- acute effect and local systemic: 1, 2, 3
- acute injury and additional role: 1, 2, 3
- acute injury and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute injury and local regulation: 1
- acute injury and local systemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute lung disease and admission time: 1
- acute lung disease and local systemic: 1
- acute lung injury and admission time: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date